- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03335215
Cognitive Remediation in Alcohol Disorders (ALCOSTIM)
November 3, 2017 updated by: University Hospital, Caen
Interest of Cognitive Remediation for the Reduction of Consumption in Alcohol Disorders
The individual and societal cost of alcohol use disorders (TUAL), present in 10% of the population in France, is considerable.
Despite psychotherapeutic and drug addiction treatment, the relapse rate remains very high, partly because of their very frequent cognitive disorders.
In fact, more than 75% of TUAL patients present to varying degrees neuropsychological alterations that are only rarely detected and never treated.
However, these cognitive disorders limit the benefit of psychotherapeutic care, reduce compliance with pharmacological treatments and hinder the patient's ability to change his behavior with respect to alcohol.
An innovative way to promote the maintenance of the therapeutic contract, and therefore to reduce alcohol consumption in these patients, would be to improve their cognitive functioning.
The objective of this study is to measure the efficacy of a non-drug treatment, based on a specific and personalized cognitive remediation program, compared to a standard treatment in Day Hospitalization, in order to reduce the rate of relapse very high in TUAL.
It is a randomized, single-blind study with two parallel groups of patients with post-weaning neuropsychological disorders: REMED (cognitive remediation) and CONTROL (usual care).
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
150
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient male or female aged 18 to 60, French speaking and affiliated to the social security system
- Patient with TUAL (DSM-5) at the forefront of alcohol use disorders at the time of inclusion
- Patient with neuropsychological disorders objectified on BEARNI (BEARNI for Brief Evaluation of Alcohol-Related Neuropsychological Evaluation, Ritz et al., 2015 cut-off cognitive score = 13, adding a point for patients with bachelor level or lower) and confirmed at the neuropsychological checkup showing pathological performance (at least two free or total recalls of RL / RI 16 <-1.65 and / or RBMT IGM <-1.65 OR number of persecutory or deficit errors at MCST <-1.65 and / or at least two BADS subtests with a score of <or = 2 (except temporal judgment)). Evaluation (BEARNI) at least 48h after stopping benzodiazepines
- Patient weaned of alcohol, that is to say between 5 and 21 days after stopping alcohol, after disappearing signs of withdrawal (Cushman score <2) and stopping benzodiazepines
- First hospitalization type day hospital (not necessarily first weaning)
- Patient having been informed of the study and being able to give written informed consent.
Exclusion Criteria:
- Patient with severe and long-lasting neurological complications related to alcohol (Korsakoff syndrome, fetal alcohol syndrome, ...)
- Patient with a disorder of severe use of another psychoactive substance according to DSM-5, except tobacco
- Patient with motor or sensory deficit making cognitive remediation impossible
- Patient previously included or already included in another biomedical research
- Homeless patient
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: usual care
|
|
Experimental: cognitive remediation
The innovative nature of this cognitive remediation program is that it integrates both neuropsychological psychoeducation, the principles of reeducation of altered cognitive functions and the setting in addictological context benefiting from the interactions of the group situation.
Thus, during the three months of REMED management, six modules corresponding to six altered cognitive domains.
The REMED group will benefit from cognitive remediation of episodic memory disorders, executive and attentional functions, and the theory of the mind integrating psychoeducation, training and systematic situations related to an alcoholic context.
|
The innovative nature of this program is that it integrates both neuropsychological psychoeducation, the principles of reeducation of altered cognitive functions and the setting in addictological context benefiting from the interactions of the group situation.
Thus, during the three months of REMED management, six modules corresponding to six altered cognitive domains that may have an impact on the maintenance of the therapeutic contract will be offered to patients.
The REMED group will benefit from cognitive remediation of episodic memory disorders, executive and attentional functions, and the theory of the mind integrating psychoeducation, training and systematic situations related to an alcoholic context.
The different procedures of neuropsychological management (facilitation, use of preserved capacities and compensation) will help to integrate the concepts and addictological strategies necessary to maintain the therapeutic contract taking into account cognitive impairments.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
total quantity of alcohol consumed in 3 months (measured in units of pure alcohol, 1 unit = 10g of alcohol).
Time Frame: baseline until 3 month of intervention
|
using TimeLine-Follow-Back tracking method (TLFB)
|
baseline until 3 month of intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
February 1, 2018
Primary Completion (Anticipated)
August 1, 2019
Study Completion (Anticipated)
February 1, 2020
Study Registration Dates
First Submitted
November 3, 2017
First Submitted That Met QC Criteria
November 3, 2017
First Posted (Actual)
November 7, 2017
Study Record Updates
Last Update Posted (Actual)
November 7, 2017
Last Update Submitted That Met QC Criteria
November 3, 2017
Last Verified
November 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17-123
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Disorders
-
National Institute on Alcohol Abuse and Alcoholism...AbbVieCompletedAlcohol Dependence | Alcoholism | Alcohol Use Disorders | Alcohol AbuseUnited States
-
Boston Medical CenterBoston University; National Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcohol Dependence | Alcohol Abuse | Unhealthy Alcohol Use | Risky Alcohol Consumption Amounts | Hazardous Alcohol UseUnited States
-
University of New MexicoThe Mind Research NetworkActive, not recruitingAlcohol Drinking | Alcohol Dependence | Alcohol Use Disorder | Alcohol AbuseUnited States
-
University of Colorado, DenverUnknownAlcohol Use Disorders | Unhealthy Alcohol UseUnited States
-
Charles Drew University of Medicine and ScienceWithdrawnAlcohol Drinking | Alcohol Use Disorder | Alcohol Abuse | Alcohol Problem
-
Kent State UniversityCompletedAlcohol Use Disorder | Alcohol Abuse | Alcohol Abuse, EpisodicUnited States
-
Karolinska InstitutetCompletedAlcohol Drinking | Alcohol Dependence | Alcohol; Harmful Use | Alcohol Use Disorder | Alcohol AbuseSweden
-
Karolinska InstitutetRegion Stockholm; Public Health Agency of SwedenCompletedAlcohol Dependence | Alcohol Use Disorder | Alcohol Abuse | Harmful Alcohol UseSweden
-
Karolinska InstitutetRegion StockholmCompletedAlcohol Dependence | Alcohol Use Disorder | Alcohol Abuse | Harmful Alcohol UseSweden
-
Kaiser PermanenteNORC at the University of Chicago; Agency for Healthcare Research and Quality... and other collaboratorsCompleted
Clinical Trials on cognitive remediation
-
Queen's UniversityCompleted
-
Queen's UniversityPfizerCompleted
-
Yale UniversityCompletedCancer | Cancer of the ProstateUnited States
-
Fundació Sant Joan de DéuCompletedIndication for Modification of Patient Cognitive StatusSpain
-
VA Office of Research and DevelopmentRecruiting
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH); Columbia UniversityCompletedSchizophrenia | Schizoaffective DisorderUnited States
-
Queen's UniversityCompleted
-
Douglas Mental Health University InstituteMcGill University; Canadian Institutes of Health Research (CIHR)Recruiting
-
Gemma Garrido GarcíaCompleted
-
Institut BergoniéUniversity of Bordeaux; Association OncogiteRecruiting